The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) delivered improvements in progression-free survival (PFS) vs bortezomib (Velcade) plus lenalidomide and dexamethasone (VRd) in patients with newly…
KRd Improves PFS vs VRd in Newly Diagnosed Multiple Myeloma | Targeted Oncology
